Kyverna Therapeutics
KYTX
88 hedge funds and large institutions have $240M invested in Kyverna Therapeutics in 2024 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 34 increasing their positions, 12 reducing their positions, and 30 closing their positions.
183% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 12
2.87% more ownership
Funds ownership: 71.21% → 74.08% (+2.9%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 30
2% less funds holding
Funds holding: 90 → 88 (-2)
53% less call options, than puts
Call options by funds: $48K | Put options by funds: $102K
69% less capital invested
Capital invested by funds: $762M → $240M (-$523M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$18.6M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$16M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.5M |
| 4 |
BlackRock
New York
|
+$10.8M |
| 5 |
DM
Deerfield Management
New York
|
+$7.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$34.7M |
| 2 |
CC
Commodore Capital
New York
|
-$22.7M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$15M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$12.4M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$11.8M |
KYTX Hedge Fund Activity: Q2 2024 in Review
88 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q2 2024, worth a combined $240M — down 69% from $762M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of KYTX and 28 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 34 added.
The largest buyer was JP Morgan Chase, adding an estimated $18.6M. The largest seller was Jennison Associates, exiting entirely with an estimated $34.7M sold.
- 88 institutional investors held Kyverna Therapeutics (KYTX) as of Q2 2024, down from 90 in Q1 2024.
- Funds reported $240M of Kyverna Therapeutics stock for Q2 2024, down 69% quarter-over-quarter.
- 28 funds opened new Kyverna Therapeutics positions in Q2 2024 and 30 closed out, a net change of -2 holders.
- The largest Kyverna Therapeutics buyer in Q2 2024 was JP Morgan Chase, an estimated $18.6M added.
- The largest Kyverna Therapeutics seller in Q2 2024 was Jennison Associates, an estimated $34.7M sold.
Based on aggregated 13F filings for Q2 2024.